CCM
PTCT icon

Cadence Capital Management’s PTC Therapeutics PTCT Stock Holding History

Cadence Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-59,348
Closed -$2M – 699
2018
Q2 		$2M Buy
+59,348
New +$1.85M 0.12% 231
2015
Q1 		– Sell
-16,320
Closed -$845K – 640
2014
Q4 		$845K Buy
+16,320
New +$718K 0.05% 437

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Cadence Capital Management's PTCT Position: Q3 2018 in Review

Cadence Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2018, closing a stake of 59,348 shares — an estimated $2M sold.

Cadence Capital Management first reported a position in PTCT in Q4 2014 and held it in 2 quarters. The position peaked at $2M in Q2 2018. 180 funds tracked by Wall St. Rank hold PTCT as of Q3 2018.

  • Cadence Capital Management reported no remaining PTC Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Cadence Capital Management sold 59,348 PTC Therapeutics shares in Q3 2018, an estimated $2M.
  • Cadence Capital Management first reported a position in PTC Therapeutics in Q4 2014 and held it in 2 quarters.
  • Cadence Capital Management's PTC Therapeutics position peaked at $2M in Q2 2018.
  • 180 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2018.

Based on Cadence Capital Management's 13F filing for Q3 2018, filed 2 Nov 2018.